NEW YORK (GenomeWeb) – Agilent Technologies reported after the close of the market Wednesday that its third quarter revenues increased 3 percent year over year, with growth in its CrossLab Group and Diagnostics and Genomic Group partially offset by a decline for its Life Sciences and Applied Markets Group.

For the three months ended July 31, 2016, Agilent reported total revenues of $1.04 billion, up from $1.01 billion in the third quarter of 2015. It fell just shy of the average analyst estimate for revenues of $1.05 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.